Home » Business News » 2011 » December » December 22, 2011

Novo Nordisk files for regulatory approval of the ultra-long-acting insulin Degludec in Japan

December 22, 2011 - Bagsvaerd, Denmark

Novo Nordisk today announced the submission to the Japanese Pharmaceuticalsand Medical Devices Agency, PMDA, of a new drug application for the approvalof ultra-long-acting insulin Degludec. This new-generation basal insulin hasbeen developed for the treatment of people with type 1 and type 2 Diabetes.

Company Announcemen no 80 / 2011:

This announcement is distributed by Thomson Reuters on behalf ofThomson Reuters clients. The owner of this announcement warrants that:

(i) the releases contained herein are protected by copyright and other applicable laws; and

(ii) they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Novo Nordisk A/S via Thomson Reuters ONE



Katrine Sperling
Tel: (+45) 4442 6718
Email Contact

In North America:
Ken Inchausti
Tel: (+1) 609 514 8316
Email Contact


Klaus Bülow Davidsen
Tel: (+45) 4442 3176
Email Contact

Frank Daniel Mersebach
Tel: (+45) 4442 0604
Email Contact

Lars Borup Jacobsen
Tel: (+45) 3075 3479
Email Contact

Jannick Lindegaard
Tel: (+1) 609 786 4575
Email Contact


Comment on this story